CVC Strategic Opportunities II has agreed to exit its investment in Genetic S.p.A., an Italian pharmaceutical CDMO, transferring ownership to NB Renaissance and NB Aurora, alongside an increased stake from the founding Pavese family.

Headquartered in Fisciano, Genetic specialises in the development and manufacture of respiratory, ophthalmic, and oncology products. Its technologies include Blow-Fill-Seal, metered dose inhalers, nasal sprays, and eye drops, with products distributed both globally through pharma partners and locally via its Genetic Farma arm.

Under CVC’s ownership since 2020, the company has expanded from 20 to over 40 international markets, broadened its research pipeline, and committed to a new production facility to support increasing global demand. These developments have resulted in Genetic more than doubling its revenues over five years.

“This successful exit reflects the strong collaboration between our teams and the Pavese family,” said Michael Lavrysen, Partner at CVC Strategic Opportunities. “We are proud to have supported Genetic’s impressive growth.”

The deal highlights CVC’s strategic focus on founder-led businesses in the Italian market. It is subject to customary regulatory approvals. Rothschild & Co., PedersoliGattai, FRM Tax, BCG, and PwC advised CVC on the transaction.

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com. 

Can`t stop reading? Read more.